The application and the clinical development of nanomedicines strongly requires a deep study on the complex dynamics that happen after in vivo administration. Particularly, plasma proteins tend to associate to nanoparticles, forming a new surface named the “protein corona” that can have a strong impact on biodistribution, targeting efficacy, and toxicity.















